Biophytis (BPTSY) launches Hong Kong JV for BIO101 with up to $20M backing

Rhea-AI Filing Summary

Biophytis SA has officially registered its Hong Kong joint venture, Biophytis Biopharmaceutical Group Limited, a key step in its Asia strategy. The new entity will develop and commercialize BIO101, particularly for treating sarcopenia, and support clinical programs in Asian markets.

Operational closing will include the transfer of Biophytis’ intellectual property to the joint venture and a first investment tranche of $3 million from Asian partners. Total secured funding can reach up to $20 million over three years, enabling trial preparation, regulatory submissions, site openings in China and Japan, and team recruitment. The joint venture is expected to be operational starting in July 2026.

Positive

• Funded Asian expansion for BIO101: The Hong Kong joint venture comes with a first investment tranche of $3 million and total secured funding of up to $20 million over three years to support BIO101 clinical and commercial development in Asia.

Negative

• None.

Insights

Biotech strategy analyst

Biophytis secures funded Asia JV to drive BIO101 development.

Biophytis has formally established a Hong Kong joint venture to develop and commercialize BIO101 in Asia, focused on sarcopenia. This structure anchors its previously announced Asian partnership in a dedicated vehicle with regional execution responsibility.

The agreement links staged funding to clinical development, with a first $3 million tranche at operational closing and total secured funding of up to $20 million over three years. This provides non‑U.S., non‑European capital support for BIO101, which is described as Phase 3 ready in sarcopenia and Phase 2 ready in obesity.

The filing states the joint venture should be operational from July 2026, enabling preparatory work, regulatory submissions, and site activation in China and Japan. Subsequent disclosures on trial initiation, patient enrollment, and further tranche releases tied to development milestones will clarify how effectively this structure accelerates BIO101 in Asian markets.

Key Figures

Initial investment tranche: $3 million Total secured funding: up to $20 million JV operational timing: July 2026 +3 more

6 metrics

Initial investment tranche $3 million First tranche from Asian partners at operational closing

Total secured funding up to $20 million Funding over three years tied to clinical development

JV operational timing July 2026 Joint venture expected to be operational starting July 2026

BIO101 sarcopenia stage Phase 3 ready to start Development stage for sarcopenia indication

BIO101 obesity stage Phase 2 ready to start Development stage for obesity indication

Funding period three years Duration over which up to $20 million may be disbursed

Key Terms

joint venture, sarcopenia, Phase 3, Phase 2, +2 more

6 terms

joint venture financial

"announces the official registration of its joint venture in Hong Kong"

A joint venture is when two or more companies team up to work on a specific project or business idea, sharing both the risks and the rewards. It’s like friends starting a lemonade stand together—each contributes resources and they split the profits, making it easier to succeed than going alone.

sarcopenia medical

"developing and commercializing BIO101 in the region, particularly for the treatment of sarcopenia"

Phase 3 medical

"BIO101 ... for muscular diseases (sarcopenia, Phase 3 ready to start)"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

Phase 2 medical

"metabolic disorders (obesity, Phase 2 ready to start)"

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

American Depositary Shares financial

"its ADS (American Depositary Shares) are listed on the OTC market"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

clinical-stage biotechnology company financial

"Biophytis SA is a clinical-stage biotechnology company focused on developing drug candidates"

FAQ

What did Biophytis (BPTSY) announce regarding its Asia strategy?

Biophytis announced the official registration of its Hong Kong joint venture, Biophytis Biopharmaceutical Group Limited, to develop and commercialize BIO101 in Asia. This entity supports clinical programs, particularly in sarcopenia, and is central to the company’s broader international expansion strategy.

How much funding is associated with Biophytis’ new Asia joint venture?

The joint venture includes a first investment tranche of $3 million from Asian partners at operational closing. In total, secured funding can reach up to $20 million over three years, disbursed in stages tied to BIO101’s clinical development milestones in the region.

When will Biophytis’ Asia joint venture become operational?

Biophytis states that the joint venture will be operational starting in July 2026. Once operational, it will launch preparatory work for clinical trials in Asia, file authorization applications, open clinical centers in China and Japan, and recruit the management team.

What role will the joint venture play in Biophytis’ BIO101 program?

The joint venture will develop and commercialize BIO101 in Asia, initially focusing on sarcopenia. It will manage trial preparation, regulatory submissions, site openings in China and Japan, and organizational build‑out, supporting progression of BIO101, which is described as Phase 3 ready in sarcopenia.

What is the total potential investment over three years for Biophytis’ Asia venture?

The agreement provides total secured funding of up to $20 million over three years. These amounts are to be disbursed in stages based on clinical development progress, following an initial $3 million tranche linked to the joint venture’s operational closing.

Which indications is Biophytis’ lead candidate BIO101 targeting?

BIO101 (20‑hydroxyecdysone) is Biophytis’ lead candidate for age‑related diseases. It is in development for muscular diseases such as sarcopenia, described as Phase 3 ready to start, and for metabolic disorders such as obesity, described as Phase 2 ready to start.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Accepted by SEC EDGAR 06/09/2026 - 11:33 AM Learn about SEC filing dates

UNITED STATES SECURITIES

AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Date of report: June 9, 2026

Commission File Number: 001-38974

BIOPHYTIS S.A.

(Translation of registrant’s name into English)

Stanislas Veillet
Biophytis S.A.

Sorbonne University—BC 9, Bâtiment A 4ème étage

4 place Jussieu

75005 Paris, France

+33 1 44 27 23 00

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

x Form 20-F ¨ Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

On June 9, 2026, Biophytis S.A. issued a press release announcing the official registration of its joint venture in Asia. A copy of the press release is attached as Exhibit 99.1 to this Form 6-K.

EXHIBIT LIST

Exhibit		Description
99.1		Press Release dated June 9, 2026.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	BIOPHYTIS S.A.
Date: June 9, 2026	By:	/s/ Stanislas Veillet
		Name: Stanislas Veillet
		Title: Chairman and Chief Executive Officer

Exhibit 99.1

 

New strategic Milestone for Biophytis:

Official Establishment of Its Joint Venture in Asia

Paris (France) and Cambridge (Massachusetts, United States), June 9^th, 2026 at 7.00 AM (CET) – Biophytis SA (Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a pioneer in the development of transformative therapies impacting longevity, today announces the official registration of its joint venture in Hong Kong, Biophytis Biopharmaceutical Group Limited, marking a decisive milestone in the implementation of the strategic partnership in Asia, which was announced on January 28, 2026.

This new entity represents a major step in Biophytis’ international strategy to strengthen its presence in Asia. It will be tasked with developing and commercializing BIO101 in the region, particularly for the treatment of sarcopenia.

Stanislas Veillet, Chairman and CEO of Biophytis, said: “The registration of our joint venture in Hong Kong is an essential milestone in the execution of our strategic agreement in Asia. We are moving with determination toward the operational closing of this operation, which will pave the way for the concrete launch of our clinical program in Asian markets. Our partnership confirms the appeal of BIO101 and strengthens our ability to address the immense unmet medical need represented by sarcopenia, in Asia as well as in Europe.”

Next Steps Toward Operational Launch

The registration of the joint venture clears the way for the operational closing, which will simultaneously include the effective transfer of Biophytis’ intellectual property to the joint venture and the injection of the first investment tranche of $3 million by the Asian partners.

This first tranche of funding will enable the immediate launch of preparatory work for the clinical trial in Asia, the submission of applications for authorization to begin the trial, the opening of clinical centers in China and Japan, and the recruitment of the management team. The joint venture will be operational starting in July 2026. As a reminder, the total secured funding amounts to up to $20 million over three years, disbursed in stages based on clinical development, in accordance with the agreement announced in January 2026.

***

About BIOPHYTIS

Biophytis SA is a clinical-stage biotechnology company focused on developing drug candidates for age-related diseases. BIO101 (20-hydroxyecdysone), our lead drug candidate, is a small molecule in development for muscular diseases (sarcopenia, Phase 3 ready to start) and metabolic disorders (obesity, Phase 2 ready to start). The company is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil. The Company’s ordinary shares are listed on Euronext Growth Paris (ALBPS - FR001400OLP5) and its ADS (American Depositary Shares) are listed on the OTC market (BPTSY - US 09076G401). For more information, visit www.biophytis.com.

Biophytis Contacts

Investor Relations

investors@biophytis.com

Media contacts

Antoine Denry: antoine.denry@taddeo.fr – +33 6 18 07 83 27

Nizar Berrada: nizar.berrada@taddeo.fr – +33 6 38 31 90 50

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EXHIBIT 99.1 7.0 KB